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Abstract
Objective. The B cell chemoattractant chemokine ligand 13 (CXCL13) is emerging as a new biochemical
marker in RA. This study was undertaken to dissect the relationship between CXCL13 expression levels in
the synovium and clinico-pathological variables relevant to RA pathogenesis and outcome.
Methods. Synovial tissues from 71 RA patients were evaluated by immunohistochemistry. Thirty paired
samples were used for comparative gene expression analysis by quantitative real-time PCR. CXCL13
levels were analysed in relation to cellular, molecular and clinical features of inflammation, lymphocyte
activation and joint damage.
Results. In patients with early disease (<12 months duration), CXCL13 expression correlated significantly
with synovial markers of local disease activity and systemic inflammation. Such correlation was less
evident in established RA. Notably, the association with lymphocyte infiltration and with expression of
B/T cellrelated activation and proliferation genes, such as activation-induced cytidine deaminase, IFN-g
and IL-2, remained highly significant independent of disease duration and local disease activity. Patients
featuring the highest levels of CXCL13 were more frequently ACPA positive and IgG ACPA titres were
increased in the high CXCL13 expression group. Furthermore, the frequency of erosive disease on radio-
graphs was significantly higher in the upper tertile of CXCL13 expression (P= 0.01 with adjustment for
disease duration and ACPA). Accordingly, synovial CXCL13 and the local receptor activator of nuclear
factor kB ligand (RANKL)/osteoprotegerin (OPG) ratio significantly co-varied (= 0.52, P< 0.01), independ-
ent of the level of local inflammation.
Conclusion. Synovial CXCL13 appears to be a marker of a more severe pattern of RA disease, char-
acterized by increased lymphocyte activation and bone remodelling beyond the level of conventional
markers of inflammation.
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Introduction
Management of RA has steadily improved in recent dec-
ades, mostly due to enhanced understanding of the
pathophysiology of the disease, which has been trans-
lated into effective therapies. However, despite the re-
markable successes achieved, the clinical complexity
and the varied response to therapy leave multiple chal-
lenges in RA management. The wide heterogeneity in clin-
ical manifestations, courses and outcomes of the disease
continues to be largely unexplained, hampering the pos-
sibility of tailored approaches. At present, with the
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exception of ACPA [1], most of the parameters used to
accommodate the variance of RA are based on non-spe-
cific demographic, clinical and laboratory features [2, 3].
Markers embedded in the underlying disease mechan-
isms represent potentially superior tools for the patho-
physiological and clinical stratification of RA. Analysis of
the primary involved tissue, such as the synovial mem-
brane, may help in both generating novel biomarkers
through non-targeted, data-driven approaches and eval-
uating the impact of hypothesis-driven parameters [35].
Using a computer model representing the biology of the
rheumatic joint, the B cell attracting chemokine CXC
chemokine ligand 13 (CXCL13) [or B lymphocyte chemo-
attractant (BLC) or B cell attracting chemokine 1 (BCA-1)]
has been recently identified as a new potential serologic
marker for severity in RA [6]. Serum levels of CXCL13 have
been further confirmed to be associated with synovial in-
flammation on clinical examination [7, 8] and with synovitis
persistence on imaging [7]. Although investigation of the
sources of circulating CXCL13 is ongoing [8], the involve-
ment of the chemokine in the pathology of synovitis in RA
has long been acknowledged. Synovial ectopic expres-
sion of CXCL13 can be induced in a variety of cell
types, including follicular dendritic cells, a proportion of
CD14+/CD68+ monocytes/macrophages, and a subset of
memory T cells [911]. CXCL13 produced locally is asso-
ciated with the formation of extra-nodal lymphoid aggre-
gates, which represent the primary environment for
ectopic B lymphocyte interactions with other cell subsets
[12] as well as for local affinity maturation of the
immunoglobulin genes [13, 14]. Experimental evidence in
physiologic conditions and in different pathological set-
tings indicate that, in addition to mediating recruitment
and clustering of B cells through its cognate receptor
CXCR5 [15], CXCL13 enhances B cell receptor-mediated
B cell activation [16], guides migration of CXCR5+CD4+
follicular helper T cells [17] and possibly impacts on
other CXCR5-bearing cells, including dendritic cells [18]
and bone cells [19, 20]. Supporting a role for CXCL13 as
an important mediator of autoimmune arthritis, neutraliza-
tion of CXCL13 or CXCR5 gene deletion significantly
reduced disease severity in animal models of arthritis
[2123].
Expression levels of CXCL13 in the synovium vary wide-
ly among patients with RA [911], but the regulatory
determinants and the effects of this variation on synovial
pathobiology and clinical features of RA are currently un-
clear. In the clinical setting for CXCL13 to function as a
candidate biomarker, it is critical to have a better under-
standing of whether tissue gradients of CXCL13 could
reflect differences in the underlying pathology and even-
tually impact the clinical features of the disease or simply
represent another non-specific marker of inflammation.
Here we investigated this hypothesis, analysing the bio-
molecular and clinical characteristics of inflammation,
immune cell activation and bone damage in RA in relation
to the expression levels of CXCL13 in the joint.
Patients and methods
Patients
Synovial tissue was obtained from 71 consecutive RA pa-
tients fulfilling the 1987 ACR criteria. All patients gave
informed consent for synovial sampling and the study
was approved by the Ethical Committee of the IRCCS
Policlinico San Matteo Foundation, Pavia, Italy
(20070001302). Demographic and clinical data at the
time of tissue collection are reported in Table 1. None of
the patients were being treated or had been previously
treated with biologic agents. The presence of IgM
RF and IgG ACPA was determined by nephelometry
using the N Latex RF system (Dade Behring, Marburg,
Germany) and a second-generation ELISA (Axis-Shield,
Dundee, UK) respectively, according to the manufac-
turers’ recommendations. Erosive disease in the overall
cohort was defined when at least one typical bone erosion
[24] was seen on the hands and feet on plain radiographs
evaluated by two independent experienced rheumatolo-
gists (C.M. and R.C.) blinded to histological and molecular
findings. In the subgroup of patients with a disease dur-
ation <12 months who were DMARD free (n= 20), bone
erosions were additionally evaluated according to the
Sharpvan der Heijde score (SHS) [25].
Synovial tissue collection
Synovial tissues were obtained from synovectomy, arthro-
scopic or US-guided biopsy from an actively inflamed
knee (n= 58), wrist or MCP joint (n= 13). According to cur-
rent recommendations, at least six samples were taken
TABLE 1 Main demographic and clinical characteristics of
the study population
Patients
(n=71)
Age, mean (S.D.), years 55.4 (13.9)
Female, n (%) 49 (69)
Disease duration, median (IQR), months 48 (11120)
Number of tender joints, median (IQR) 4 (113)
Number of swollen joints, median (S.D.) 9 (518)
DAS, mean (S.D.) 3.25 (1.14)
ESR, median (IQR), mm/h 27 (1756.8)
CRP, median (IQR), mg/dl 1.5 (0.44.1)
HAQ, mean (S.D.) 1.1 (0.76)
RF positive, n (%) 43 (60.6)
ACPA positive, n (%) 36 (50.7)
Erosive disease, n (%) 44 (62)
Patients on corticosteroids, n (%) 44 (62)
Patients on DMARDs, n (%) 51 (71.8)a
MTX 29 (40.8)
HCQ 19 (26.8)
SSZ 9 (12.7)
Patients on more than one DMARD, n (%) 6 (8.5)
Number of previous DMARDs,
median (IQR)
0 (01)
IQR: interquartile range. aTwenty patients (28.2%) with dis-
ease duration <12 months were DMARD free.
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from different sites during arthroscopic biopsies and eight
during US-guided biopsies [26, 27]. Specimens were
either immersed in a 5:1 (v:v) mixture of RNAlater for
RNA extraction (see below) or fixed in 10% formalin for
24 h, embedded in paraffin, sectioned at 4 mm and pro-
cessed for histology and immunohistochemistry.
Immunohistochemistry
The expression of CXCL13 and cellular markers was ana-
lysed by immunohistochemistry on consecutive sections
as previously described [28]. Briefly, formalin-fixed, paraf-
fin-embedded tissue sections were deparaffinized and
rehydrated through graded ethanols. After heat retrieval
for 35 min at 96C in Target Retrieval Solution (S1700;
DAKO, Glostrup, Denmark), sections were blocked with
Protein Block Serum Free (X0909; DAKO) for 10 min. The
following primary antibodies were used: anti-CXCL13
(polyclonal; R&D Systems, Minneapolis, MN, USA), anti-
CD68 (PG-M1; DAKO) for macrophages, anti-CD20 (L26;
DAKO) for B cells, anti-CD3 (polyclonal; DAKO) for T cells
and anti-CD138 (MI15; DAKO) for plasma cells. Sections
were then incubated with the appropriate biotinylated
secondary antibody for 30 min followed by streptavidin
biotin complexalkaline phosphatase (AK-5000; Vector
Laboratories, Burlingame, CA, USA) or, for CD68 macro-
phages, by streptavidin biotin complexhorseradish per-
oxidase (PK-6100; Vector Laboratories) for an additional
30 min. Stainings were developed using the New Fuchsin
Substrate Kit (K0625; DAKO) or, for CD68 macrophages,
liquid 3,30-diaminobenzidine in chromogen solution
(K3467; DAKO). Concentration- and isotype-matched
control antibodies were included as a negative control
and tonsil sections were included as a positive control.
Histological and immunohistochemical evaluation
Samples were blindly analysed by two independent
observers (S.B. and B.V.) in a randomized order on two
different occasions. All the evaluations were standardized
by analysis of a separate set of slides prior to analysis of
the study samples. The analysis included all areas of each
biopsy section. Samples without intact lining were
ignored.
Because of the high heterogeneity of RA synovium
and the low frequency of CXCL13+ cells, quantification
of positive cells was performed on hot spots, defined as
areas containing the highest density of positive cells [29].
Two hot spots per synovium were selected. In each spot,
positive cells were counted in 10 consecutive fields
at 400 magnification. One field corresponded to
0.55 mm2, and thus one spot corresponded to 11 mm2.
The number of positive cells per two hot spots was
averaged and the results were expressed as the number
of positive cells per square millimetre. CXCL13+ cell dens-
ity was then categorized as low or high based on tertile
distribution.
Each tissue was assigned a score for hyperplasia of
the synovial lining layer (0: 12; 1: 34; 2: 56; 3: >7 cell
layers) [30]. Infiltration with CD68+ sublining macro-
phages, CD3+ T lymphocytes and CD138+ plasma cells
was evaluated semi-quantitatively (03) according to vali-
dated methods [31]. CD20+ B cell infiltration was as-
sessed as an aggregational gradient. B cell aggregates
were first graded according to their radial cell count,
adapting published methods [32]. The B cell aggregational
score was then defined semi-quantitatively, combining
the size and sublining density distribution of CD20+ B
cell aggregates: 0 = no B cell aggregates/low-density
(<3 aggregates in the whole biopsy area) grade (G)1 B
cell aggregates; 1 = high-density G1/low-density G2;
2 = high-density G2/low-density G3; 3 = high-density G3
B cell aggregates. Validation studies performed in our
laboratories confirmed a highly significant correlation be-
tween this scoring system and CD19 mRNA expression
assessed in the same samples by real-time PCR [= 0.71,
P= 0.0004 by Spearman’s rank correlation (not shown)].
All semi-quantitative scores showed excellent intra- and
interobserver agreement (50.85) and never differed by >1
point. When discordant scores were obtained, the mean
of the two scores was used.
Quantitative real-time PCR
From 30 of the 71 patients, paired paraffin and RNA
samples were available and used for comparative
immunohistochemistry analysis and real-time quantitative
PCR (qPCR). The main demographic and clinical features
of the subgroup of patients used for qPCR analyses were
comparable to the overall population. The median disease
duration was 48 months [interquartile range (IQR) 10108],
46.7% of the patients were ACPA positive and 63.3% had
erosive disease on radiographs.
Each specimen was divided into two parts: one was
formalin fixed and paraffin embedded and the second
was stored in RNAlater (Ambion, Austin, TX, USA) at
80C for RNA extraction and qPCR analysis, as previ-
ously described [13]. Briefly, total RNA was extracted
using the RNeasy Mini Kit (Qiagen, Venlo, The
Netherlands), with on-column DNase I digestion to avoid
genomic DNA contamination. cDNA was generated from
1mg of RNA using the Thermoscript RT-PCR System for
First-Strand cDNA Synthesis (Invitrogen, Carlsbad, CA,
USA). A detailed list of the genes investigated and the
specific primers and probes is available in supplementary
Table S1, available at Rheumatology Online. The reverse
transcription (RT)-PCR was run in triplicate with an equal
loading of 20 ng of cDNA per well. The results were ana-
lysed after 40 cycles of amplification using an Realplex
PCR machine (Eppendorf, Hauppauge, NY, USA).
Relative quantification was measured using the compara-
tive CT (threshold cycle) method after normalization for
b-actin expression levels. cDNA from tonsil was used as
a positive control.
Statistical analysis
Demographic and clinical features were described as
mean (S.D.), median (IQR) or relative frequency, as appro-
priate. One-way analysis of variance (ANOVA)
tests, KruskalWallis tests and chi-squared statis-
tics were used to compare histopathological and
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immunohistochemistry scores, mRNA levels and clinical,
laboratory and radiographic data among different CXCL13
tertiles, when appropriate. Correlations among mRNA
levels were computed by Spearman’s rho correlation co-
efficients. The association of high CXCL13 with erosive
disease on radiographs was evaluated by means of uni-
variable and multivariable logistic models fitted to account
for potential confounders (disease duration, ACPA posi-
tivity). MedCalc for Windows, version 9.4.2.0 (MedCalc
Software, Mariakerke, Belgium), was used for analysis.
P-values <0.05 were considered significant.
Results
Heterogeneity of synovial CXCL13 expression and
validation of CXCL13+ cell quantification
The distribution of CXCL13+ cells in the synovium was
evaluated in all 71 patients included in the study. The
mean CXCL13+ cell density was extremely variable
across different samples, ranging from 0 to 44.6 cells/
mm2 [median 7.2 cells/mm2 (IQR 1.812.6)] (Fig. 1A).
Confirming the reliability of our manual counting, cell
density computed by the hot spot analysis was strongly
correlated with CXCL13 mRNA (= 0.92, P< 0.001)
(Fig. 1B). Also, CXCL13 mRNA levels progressively
increased when cell density was categorized as low or
high based on the tertile distribution (Fig. 1C). Although
CXCL13+ cells were slightly increased in samples
obtained from the small joints of the hands and wrists
compared with the knees (12.1 vs 8.7 cells/mm2), the dif-
ference was not statistically significant. Similarly, no dif-
ferences in CXCL13 expression were observed in relation
to disease duration.
CXCL13 expression and synovial tissue biomarkers
of disease activity
In the overall cohort, increasing CXCL13+ cell density
scores (categorized based on the tertile distribution)
showed a progressive increase in the degree of CD68+
sublining macrophage infiltration (Fig. 2A) and the lining
layer thickness (Fig. 2B), two validated histological mar-
kers of local disease activity and systemic inflammation
FIG. 1 Synovial CXCL13 expression in patients with RA
Quantification of synovial CXCL13+ cells in the overall cohort (n= 71) was performed according to the hot spot method of
analysis. Manual cell counting on paraffin sections was validated against CXCL13 mRNA quantitative expression on
paired samples (n= 30). CXCL13+ cell density was further categorised based on the tertile distribution and reassessed for
CXCL13 mRNA. (A) Representative examples of different degrees of synovial CXCL13+ cell density (tertiles 13) in
specimens from three independent patients with RA are shown. Original magnification 100. (B) Scatter diagram
showing the CXCL13+ cell count plotted against CXCL13 mRNA expression in single samples (empty circles) and the
corresponding regression line. (C) Bar graph showing the mean (S.D.) CXCL13 mRNA expression levels stratified
according to tertiles of synovial CXCL13+ cell density.
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[31, 33, 34]. When patients were partitioned based on dis-
ease duration, the associations were highly significant in
early disease (<12 months from onset of symptoms)
(Fig. 2C and D), while statistical significance was lost for
longer duration (Fig. 2E and F). Accordingly, the correl-
ation of CXCL13 mRNA levels with a preselected panel
of proinflammatory cytokines shown to be up-regulated
in the RA joint was variable, being significant for IL-17A
(= 0.5, P= 0.01) and IL-1b ( 0.55, P= 0.003) but not for
TNF-a and IL-6, as shown in Fig. 2GL, where the vari-
ations of proinflammatory genes in relation to synovial
CXCL13+ cell density scores are illustrated. No associ-
ation was found with IL-10 and TGF-b expression, arguing
against a specific relationship between synovial CXCL13
induction and activation of a local anti-inflammatory re-
sponse. At the clinical level, synovial CXCL13 expression
was unrelated to composite indexes of disease activity,
such as the DAS, the 28-joint DAS (DAS28) or the SDAI, in
either early or established RA.
CXCL13 expression and markers of lymphocyte
infiltration and activation
In contrast with the variable association with synovial in-
flammatory biomarkers, a tight relationship was observed
between CXCL13 expression and markers related to
lymphocyte effector functions. Increasing CXCL13+ cell
scores were characterized by a progressive increase in
the degree of B cell and CD138+ plasma cell infiltration
(Fig. 3A and B). mRNA levels of activation-induced cyti-
dine deaminase, the enzyme required for initiating the pro-
cesses of somatic hypermutation and class switch
recombination in activated B cells [13], also showed in-
cremental expression closely matching the CXCL13+ cell
density score (Fig. 3C) as well as CXCL13 mRNA (= 0.87,
P< 0.001). Increasing CXCL13 expression was also sig-
nificantly associated with T cell enrichment (Fig. 3D), as
well as with tissue levels of the T cellspecific activation
and proliferation cytokine IL-2 and the T cell effector
factor IFN-g (Fig. 3E and F). The correlation between
FIG. 2 Association of CXCL13 expression levels with synovial inflammatory markers
Mean (S.D.) expression levels of different cellular and molecular markers of synovial inflammation stratified according
to tertiles of CXCL13+ cell density. (AF) CD68+ sublining macrophage infiltration (A, C and E) and lining layer
thickness (B, D and F) both show progressively incremental levels in the overall cohort (A and B) due to
significant increases in patients with disease duration <12 months (n= 20) (C and D). The association is non-
significant in patients with longer duration (>12 months) (E and F). (GL) Overexpression of proinflammatory
cytokines in relation to increasing CXCL13 scores is significant for (G) IL-17A and (H) IL-1b mRNA, but not for
(I) TNF-a and (L) IL-6.
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lymphocyte infiltration or markers of lymphocyte activa-
tion and CXCL13 expression was independent of disease
duration and the degree of synovial inflammation as
expressed by the CD68+ macrophage score.
To evaluate the possible relationship with clinical par-
ameters of systemic immune deregulation, synovial
CXCL13 was analysed in relation to the autoantibody
status. As shown in Fig. 3G, ACPA positivity could occur
in patients with low or undetectable synovial CXCL13
expression, and high CXCL13 (third tertile) was equally
found in a proportion of ACPA-negative patients.
However, patients in the third tertile of synovial CXCL13
were more frequently ACPA positive (71% vs 46% vs
35%, chi-squared trend P< 0.001) (Fig. 3G). In ACPA-
positive patients, high CXCL13 was also significantly
associated with higher autoantibody titres (Fig. 3H).
CXCL13 expression and bone damage
Increasing CXCL13 expression was strikingly associated
with a progressive increase in the synovial receptor
activator of nuclear factor kB ligand (RANKL)/osteoprote-
gerin (OPG) ratio. This appeared for both categorical ana-
lysis of CXCL13 based on the tertile distribution (Fig. 4A)
and for mRNA levels analysed as a continuous variable
(= 0.52, P< 0.01). Notably, this association was partly
independent of the degree of synovial tissue inflammation.
When only tissue specimens exhibiting the highest levels
of local inflammation (CD68+ sublining macrophage score
52) were analysed, the highest tertile of CXCL13 was
still associated with a 3.3-fold increase in the RANKL/
OPG ratio compared with the lower tertiles (Fig 4B).
Congruently, comparison of the highest and lowest tertiles
of CXCL13 in samples with low levels of inflammation
(CD68+ score 41) confirmed a significantly higher
RANKL/OPG ratio in the former (Fig. 4C).
In order to determine whether the observed patho-
logical findings translated into clinical features, synovial
CXCL13 expression was analysed in relation to radio-
graphic erosions. Although erosive patients were distrib-
uted across all the CXCL13 tertiles, the prevalence of
FIG. 3 Association of CXCL13 expression levels with immune cell infiltration and autoantibodies
(AF) Mean (S.D.) levels of synovial (A) CD20+ B lymphocytes, (B) CD138+ plasma cells, (C) activation-induced cytidine
deaminase (AID) mRNA, (D) CD3+ T lymphocytes, (E) IFN-g mRNA and (F) IL-2 mRNA stratified according to tertiles of
CXCL13+ cell density. All markers show highly significant incremental levels along with increasing CXCL13 expression
(P< 0.001 for all). (G) Histogram showing the frequency of ACPA-positive and -negative patients in each tertile of synovial
CXCL13 expression. (H) Bar chart showing mean (S.D.) ACPA titres in each tertile of synovial CXCL13 expression in
ACPA-positive patients.
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erosive disease progressively increased along with
increasing CXCL13 scores (Fig. 4D). Such an increase
was highly significant in samples in the third tertile (96%)
compared with samples in the second (54%, P= 0.003)
and first tertiles (35%, P< 0.0001), while no differences
were found between the second and the first tertiles
(P= 0.3). The independent association of CXCL13 in the
third tertile was maintained when other predictors of ero-
sive disease, such as ACPA positivity and disease dur-
ation, were included in a multiple logistic regression
model (OR 14.3, 95% CI 1.5, 132.4, P= 0.01). In the sub-
group of patients with a disease duration of <12 months,
although no relationship was observed with the total SHS
and the joint narrowing score (Fig. 4E and F), the highest
levels of CXCL13 expression appeared to be associated
with increased erosion subscores (Fig. 4G).
Discussion
In this study we investigated the clinico-pathological vari-
ability of RA in relation to the expression levels of CXCL13
in the joint. The analysis of a large and well-characterized
cohort of RA patients heterogeneous for disease duration
and activity allowed us to establish that gradients of
CXCL13 expression may not reflect per se the level of
synovial inflammation, as we commonly define it by
means of conventional histological/molecular markers.
Rather, CXCL13 enrichment appeared linked with an im-
munologically active lymphoid cell infiltrate and an unba-
lanced RANKL/OPG ratio that could be maintained
beyond the level of synovial inflammation and disease
stages. In keeping with such a cellular and molecular
milieu, the highest levels of CXCL13 expression were
associated with a more severe and erosive disease at
the clinical level.
Proinflammatory cytokines play a role upstream of
CXCL13 expression and lymphoid tissue organization,
as demonstrated in animal models of lymphoid tissue
ontogenesis and neogenesis [3537]. Accordingly, we
found a significant association between CXCL13 expres-
sion and conventional histological parameters reflecting
synovial inflammation in untreated RA patients with early
disease. Histopathological features associated with the
local expression of CXCL13, such as the presence of ec-
topic lymphoid structures, were also shown to be related
to synovial tissue macrophage infiltration in a previous
cohort of early arthritis [38]. However, patient stratification
for disease duration revealed that the association with
FIG. 4 Association of CXCL13 expression levels with bone damage
(A) Bar graph showing the progressive increase in the synovial receptor activator of nuclear factor kB ligand (RANKL)/
osteoprotegerin (OPG) ratio along with increasing CXCL13+ cell density tertiles. Bars represent mean (S.D.) values. (B and
C) High CXCL13 expression (third tertile) still displays an increase in the RANKL/OPG ratio compared with lower tertiles
(first and second) both in samples with high inflammatory features (CD68+ sublining macrophage score52) (B) and in
samples with low levels of inflammation (CD684 1) (C). (D) Histogram showing the frequency of patients with radio-
graphic erosions in each tertile of synovial CXCL13 expression. (E) Mean (S.D.) radiographic total scores, (F) joint space
narrowing (JSN) and (G) erosion subscores according to the Sharpvan der Heijde score (SHS) in different tertiles of
CXCL13 expression in patients with a disease duration <12 months. Significant differences are found in the erosion
subscore only.
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most of the inflammatory markers was not maintained
regularly in established RA treated with synthetic
DMARDs. Similar to our results, the correlation of either
CXCL13 or synovial lymphocyte aggregates with cellular
and molecular markers of inflammation was found incon-
sistent in previous cohorts heterogeneous for disease dur-
ation and treatment [8, 32, 39, 40]. Thus, although
CXCL13 induction, B cell recruitment and follicle forma-
tion at peripheral sites are certainly triggered by inflam-
matory stimuli, their maintenance and resolution dynamics
may only partly overlap with acute macrophage-driven in-
flammatory responses. High degrees of synovial CXCL13
expression may therefore reflect a specific and distinct
component of the overall inflammatory process,
characterized by more stable and structured biological
events [13, 22, 37].
CXCL13 produced within secondary lymphoid tissues
plays a critical role in organizing CXCR5+ lymphocytes
into follicles and coordinating adaptive immune responses
[1517]. Accordingly, increasing CXCL13 levels in our
cohort clearly reflected a gradient of local B cell infiltration
associated with a molecular signature indicative of both B
and T cell ongoing activation. There is growing evidence
indicating that synovial B cells present a strong bias to-
wards citrullinated autoantigen recognition [41], support-
ing their potential role both as (auto)antigen-presenting
cells for local T lymphocytes [12, 41] as well as direct
effectors of humoral (auto)responses [13, 14]. In our
study population, ACPA positivity occurred in the absence
of significant CXCL13 expression and lymphoid cell infil-
tration; in turn, high CXCL13 was equally found in a pro-
portion of ACPA-negative patients. Nevertheless, samples
characterized by the highest levels of CXCL13 were more
frequently ACPA positive. Furthermore, by restricting the
analysis to ACPA-positive patients and evaluating the
autoimmune response in quantitative terms, CXCL13 syn-
ovial expression levels were clearly associated with
increased ACPA titres. Collectively these data are in line
with the concept that while breach of tolerance to citrulli-
nated proteins can occur outside the joint and the auto-
immune responses can be maintained in different sites
[10, 4244], synovial B cells can contribute to local
ACPA production [13] that may concentrate in the joint
and spill over in the circulation with detectably increased
titres.
These observations also have relevance from a clinical
perspective. Since CXCL13 is not synonymous to ACPA,
the two markers may bear different/complementary clin-
ical and prognostic meanings in patients with RA [6, 7]. In
early RA, elevated serum levels of CXCL13 at baseline
have recently been shown to be associated with
increased rates of joint destruction at follow-up [6]. The
association of high CXCL13 expression in the synovium
and the erosiveness found here, independent of disease
duration and the autoantibody status, reinforces the con-
cept that CXCL13 is a marker of disease severity in RA.
Supporting our clinical findings, high CXCL13 expression
was coupled with an increase in the local RANKL/OPG
ratio, whose balance critically regulates bone remodelling
in physiologic conditions as well in inflammatory bone
loss [45]. Similarly, previous microarray screenings re-
ported a decrease in the expression of genes involved in
tissue repair in RA samples enriched in lymphocyte-
related transcripts [46]. It is important to emphasize that
correlation does not constitute evidence of causation. It is
therefore entirely possible that CXCL13 expression in the
joints of RA patients might merely represent a marker of a
chronic and/or more severe phase of the disease in which
mechanisms of joint remodelling are also independently
activated. Nonetheless, there are also clues encouraging
further studies on the potential causative role of CXCL13
(and downstream lymphoid cell infiltration/organization) in
joint remodelling. B cells were recently identified as major
producers of RANKL in the synovial fluid of RA patients
[47], and rituximab treatment strongly affects the RANKL/
OPG system as well as the genes involved in healing pro-
cesses in the synovium [48, 49]. Furthermore, and per-
haps more relevant, autoantibodies produced locally
may directly influence bone loss by promoting osteoclas-
togenesis [50].
In conclusion, local expression of CXCL13 emerges as
a marker of severe RA beyond the levels of synovial in-
flammation and ACPA status. Mechanistic studies are
warranted to establish the causeeffect relationship link-
ing CXCL13 expression, local immunity and tissue re-
modelling. From a clinical perspective, important issues
that need to be clarified for CXCL13 to be established
as an additional biomarker include the demonstration of
whether circulating levels of the chemokine reliably reflect
different synovial pathotypes and how well they outper-
form currently available tests in the clinical assessment
and prognostic stratification of RA.
Rheumatology key messages
. In RA patients, variability in synovial chemokine
ligand 13 (CXCL13) expression spans beyond con-
ventional features of local inflammation.
. The highest levels of synovial CXCL13 in RA asso-
ciate with markers reflecting immune cell activity
and bone remodelling potential.
. Synovial CXCL13 appears as a biomarker of more
severe, erosive RA.
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